IDRA News and Press, Idera Pharmaceuticals Inc. From 12/23/19

Gainers: Intra-Cellular Therapies (NASDAQ: ITCI )  +204% . More news on: Intra-Cellular Therapies, Inc., Cassava Sciences, Inc., Microbot Medical Inc., Stocks on the move, Read more ...

Idera Pharmaceuticals ( IDRA +17.6% )  sells shares of Series B1 convertible preferred stock and warrants to purchase common stock for gross proceeds of $3.9M, to an institutional investor. More news on: Idera Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

EXTON, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an institutional investor providing for a private placement exempt from the reg...

Idera Pharmaceuticals (NASDAQ: IDRA ): Q3 GAAP EPS of -$0.39 beats by $0.07 . More news on: Idera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

EXTON, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease in...

The USPTO will issue on November 5, U.S. Patent No. 10,10,463,686 to Idera Pharmaceuticals (NASDAQ: IDRA ), entitled “Immune Modulation With TLR9 Agonists For Cancer Treatment,” which includes Company’s investigational therapy tilsotolimod (IMO-2125). More news on: I...

EXTON, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, 2019 U.S. Patent No. 10,10,463,686 entitled “Immune Modulation With TLR9 Agonists For Cancer T...

EXTON, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a toll-like receptor 9 (TLR9) agonist, in combination with nivolumab, a programmed death receptor-1 (...

Orchard Therapeutics (NASDAQ: ORTX ) initiated with Overweight rating at Barclays. More news on: Orchard Therapeutics plc, Idera Pharmaceuticals, Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

Idera Pharmaceuticals (NASDAQ: IDRA ) will collaborate with AbbVie (NYSE: ABBV ) on a three-arm Phase 1b open-label clinical trial evaluating combinations of an OX40 agonist (ABBV-368), a TLR-9 agonist (tilsotolimod), chemotherapy (nab-paclitaxel) and/or an anti-programmed cell death 1 (PD...